Compare NEON & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | BRNS |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 24.1M |
| IPO Year | 1994 | 2021 |
| Metric | NEON | BRNS |
|---|---|---|
| Price | $0.87 | $0.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 296.5K | 39.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.51 |
| 52 Week High | $29.90 | $2.91 |
| Indicator | NEON | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 44.89 |
| Support Level | $0.72 | $0.56 |
| Resistance Level | $1.05 | $0.75 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 38.06 | 27.25 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.